Historical record - last NADAC effective date: 8/21/2024
Product Information
FOSAPREPITANT 150 MG VIAL is a generic product labeled by Baxter Healthcare Corporation, priced at $38.5080 per EA under NDC 00338000801. Its NADAC has been published 13 times since Aug 21, 2024.
FDA first approved this application on Sep 5, 2019.
Strength
150 mg/5mL
Manufacturer
Baxter Healthcare CorporationNDC
00338000801
Classification
Generic
Dosage Form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route
INTRAVENOUS
Effective Date
8/21/2024
Active Ingredients
FOSAPREPITANT DIMEGLUMINEApproval Type
Generic (ANDA)
FDA Application
ANDA211860FDA Approved
9/5/2019
On Market Since
9/5/2019
Pharmacological Classes
Price Statistics
The NADAC for FOSAPREPITANT 150 MG VIAL has been published 13 times since Aug 21, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $38.5080 per EA |
|---|---|
| All-time high | $38.5080 (Nov 13, 2024) |
| All-time low | $38.5080 (Aug 21, 2024) |
| Median price | $38.5080 |
| Average price | $38.5080 |
| Largest weekly change | 0.0% (Aug 28, 2024) |
| Weeks tracked | 13 |
| Tracking since | Aug 21, 2024 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
0.0%
Last surveyed Nov 13, 2024 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Fosaprepitant Dimeglumine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Baxter Healthcare Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Fosaprepitant Dimeglumine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Substance P/Neurokinin-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FOSAPREPITANT 150 MG VIAL?
The current National Average Drug Acquisition Cost (NADAC) for FOSAPREPITANT 150 MG VIAL, manufactured by Baxter Healthcare Corporation, is $38.5080 per EA (NDC 00338000801), effective Nov 13, 2024.
How has the price of FOSAPREPITANT 150 MG VIAL changed over time?
Over the history we have for it, the NADAC for FOSAPREPITANT 150 MG VIAL has held within roughly two percent of its current level. It has been tracked across 13 weekly CMS publications since Aug 21, 2024.
What are the highest and lowest recorded NADAC prices for FOSAPREPITANT 150 MG VIAL?
Since Aug 21, 2024, the NADAC for FOSAPREPITANT 150 MG VIAL has ranged from a low of $38.5080 (Aug 21, 2024) to a high of $38.5080 (Nov 13, 2024), with a median of $38.5080 per EA.
Are there cheaper alternatives to FOSAPREPITANT 150 MG VIAL?
No other NADAC-published product currently shares the active ingredient and strength of FOSAPREPITANT 150 MG VIAL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures FOSAPREPITANT 150 MG VIAL?
FOSAPREPITANT 150 MG VIAL (NDC 00338000801) is labeled by Baxter Healthcare Corporation, and CMS classifies it as a generic product.